

Title (en)
RECOMBINANT L-ASPARAGINASE

Title (de)
REKOMBINANTE L-ASPARAGINASE

Title (fr)
L-ASPARAGINASE RECOMBINANTE

Publication
EP 4048303 A1 20220831 (EN)

Application
EP 20803449 A 20201023

Priority
• US 201962926201 P 20191025
• US 202063047222 P 20200701
• EP 2020079972 W 20201023

Abstract (en)
[origin: WO2021078988A1] The present invention provides compositions and methods for treating a disease treatable by asparagine depletion in a human subject comprising administering to a human subject a recombinant L-asparaginase.

IPC 8 full level
A61K 38/50 (2006.01); **A61P 35/02** (2006.01)

CPC (source: EP US)
A61K 9/0019 (2013.01 - US); **A61K 38/50** (2013.01 - EP US); **A61P 1/00** (2017.12 - US); **A61P 35/02** (2017.12 - EP);
C12Y 305/01001 (2013.01 - US); **Y02A 50/30** (2017.12 - EP)

Citation (search report)
See references of WO 2021078988A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
WO 2021078988 A1 20210429; AU 2020371963 A1 20220526; BR 112022007677 A2 20221025; CA 3156066 A1 20210429;
EP 4048303 A1 20220831; JP 2022553399 A 20221222; TW 202134258 A 20210916; US 2021308237 A1 20211007

DOCDB simple family (application)
EP 2020079972 W 20201023; AU 2020371963 A 20201023; BR 112022007677 A 20201023; CA 3156066 A 20201023;
EP 20803449 A 20201023; JP 2022524024 A 20201023; TW 109136917 A 20201023; US 202017078376 A 20201023